Precipio Terminates Sales Agreement with A.G.P.
ByAinvest
Wednesday, Sep 3, 2025 5:49 pm ET1min read
PRPO--
Precipio's CEO, Ilan Danieli, stated, "Our company is in a much stronger position today than it was when we entered into this structure. With our elimination of negative cash flow from operations and recent increases in our cash balance, we no longer need to rely on a tool like this for capital raises." This decision marks another step in the company's strategy to create shareholder value [1].
Precipio is dedicated to addressing the pervasive problem of cancer misdiagnoses by developing innovative diagnostic products and services. Their technologies, HemeScreen and IV-Cell, are designed to improve diagnostic accuracy and efficiency. HemeScreen tests for various mutations, while IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages, streamlining the testing process [2].
The company's laboratory and research and development (R&D) facilities are located in New Haven, Connecticut, and Omaha, Nebraska. Precipio's mission is to enhance diagnostic outcomes and reduce healthcare expenses by providing higher accuracy and improved laboratory workflows.
References:
[1] https://finance.yahoo.com/news/precipio-terminates-atm-140000076.html
[2] https://www.marketscreener.com/news/precipio-terminates-its-at-the-market-instrument-ce7c50d3d08af62d
Precipio Inc., a healthcare biotechnology company, has terminated its sales agreement with A.G.P. The company is focused on cancer diagnostics and develops diagnostic products, reagents, and services to improve accuracy and efficiency. Its technologies include HemeScreen and IV-Cell, which address diagnostic mistakes and improve testing processes. Precipio has laboratory and R&D facilities in Connecticut and Nebraska.
NEW HAVEN, Conn., Sept. 02, 2025 (GLOBE NEWSWIRE) — Precipio Inc., a healthcare biotechnology company specializing in cancer diagnostics, has terminated its At-The-Market (ATM) instrument with investment bank Alliance Global Partners (AGP). This move underscores the company's commitment to responsible capital management and its growing financial stability.Precipio's CEO, Ilan Danieli, stated, "Our company is in a much stronger position today than it was when we entered into this structure. With our elimination of negative cash flow from operations and recent increases in our cash balance, we no longer need to rely on a tool like this for capital raises." This decision marks another step in the company's strategy to create shareholder value [1].
Precipio is dedicated to addressing the pervasive problem of cancer misdiagnoses by developing innovative diagnostic products and services. Their technologies, HemeScreen and IV-Cell, are designed to improve diagnostic accuracy and efficiency. HemeScreen tests for various mutations, while IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages, streamlining the testing process [2].
The company's laboratory and research and development (R&D) facilities are located in New Haven, Connecticut, and Omaha, Nebraska. Precipio's mission is to enhance diagnostic outcomes and reduce healthcare expenses by providing higher accuracy and improved laboratory workflows.
References:
[1] https://finance.yahoo.com/news/precipio-terminates-atm-140000076.html
[2] https://www.marketscreener.com/news/precipio-terminates-its-at-the-market-instrument-ce7c50d3d08af62d
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet